FY2018 EPS Estimates for AcelRx Pharmaceuticals Inc Lowered by Oppenheimer (ACRX)

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Research analysts at Oppenheimer cut their FY2018 earnings per share (EPS) estimates for shares of AcelRx Pharmaceuticals in a research report issued on Monday, November 5th. Oppenheimer analyst L. Gershell now forecasts that the specialty pharmaceutical company will post earnings of ($0.88) per share for the year, down from their previous forecast of ($0.85). Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for AcelRx Pharmaceuticals’ Q4 2018 earnings at ($0.24) EPS, Q1 2019 earnings at ($0.27) EPS, Q2 2019 earnings at ($0.30) EPS, Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.24) EPS, FY2020 earnings at ($0.98) EPS, FY2021 earnings at ($0.71) EPS and FY2022 earnings at ($0.23) EPS.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.10 million.

Several other research analysts have also recently commented on the company. Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of AcelRx Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald raised their target price on AcelRx Pharmaceuticals from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Monday, November 5th. LADENBURG THALM/SH SH set a $10.00 target price on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 2nd. Finally, ValuEngine raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $7.93.

Shares of ACRX stock opened at $3.28 on Thursday. The firm has a market capitalization of $241.44 million, a P/E ratio of -2.98 and a beta of 2.03. AcelRx Pharmaceuticals has a one year low of $1.65 and a one year high of $5.05.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in shares of AcelRx Pharmaceuticals by 16.8% during the third quarter. BlackRock Inc. now owns 786,034 shares of the specialty pharmaceutical company’s stock worth $3,026,000 after buying an additional 112,919 shares in the last quarter. Fosun International Ltd purchased a new stake in shares of AcelRx Pharmaceuticals during the third quarter worth about $1,940,000. Cedar Wealth Management LLC grew its holdings in shares of AcelRx Pharmaceuticals by 182.5% during the third quarter. Cedar Wealth Management LLC now owns 33,895 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 21,895 shares in the last quarter. Creative Planning grew its holdings in shares of AcelRx Pharmaceuticals by 256.1% during the third quarter. Creative Planning now owns 45,222 shares of the specialty pharmaceutical company’s stock worth $174,000 after buying an additional 32,522 shares in the last quarter. Finally, Lincoln Capital Corp grew its holdings in shares of AcelRx Pharmaceuticals by 83.3% during the third quarter. Lincoln Capital Corp now owns 62,775 shares of the specialty pharmaceutical company’s stock worth $242,000 after buying an additional 28,525 shares in the last quarter. 8.58% of the stock is owned by institutional investors.

In other AcelRx Pharmaceuticals news, insider Lawrence G. Hamel sold 6,953 shares of AcelRx Pharmaceuticals stock in a transaction on Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the completion of the transaction, the insider now directly owns 24,371 shares of the company’s stock, valued at $109,669.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Badri N. Dasu sold 28,351 shares of AcelRx Pharmaceuticals stock in a transaction on Monday, October 15th. The shares were sold at an average price of $5.00, for a total value of $141,755.00. Following the transaction, the insider now directly owns 54,061 shares of the company’s stock, valued at $270,305. The disclosure for this sale can be found here. 25.50% of the stock is currently owned by company insiders.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: Why Dividend Stocks May Be Right for You

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply